Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.41 |
| ▸ | AGER | Q15109 | 2/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | DCUN1D1 | Q96GG9 | 4/20 | 0.39 |
| ▸ | UBE2M | P61081 | 3/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3885750 | 1.00 | OPRM1 (0.41) | OPRM1AGERMTNR1ACHRM2CHRM3 | |
| SCHEMBL15521608 | 0.76 | DCUN1D1 (0.60) | OPRM1AGERMTNR1ATACR1DCUN1D1 | |
| SCHEMBL1460765 | 0.76 | AGER (0.43) | OPRM1AGERMTNR1ACHRM2CHRM3 | |
| SCHEMBL6031045 | 0.76 | AGER (0.43) | OPRM1AGERMTNR1ACHRM2CHRM3 | |
| Trifluoroacetic Acid SCHEMBL19920867 | 0.72 | MC4R (0.44) | OPRM1AGERMTNR1ACHRM2CHRM3 | |
| SCHEMBL3892927 | 0.71 | KMT2A (0.43) | DCUN1D1UBE2M | |
| SCHEMBL3897258 | 0.71 | KMT2A (0.43) | DCUN1D1UBE2M | |
| SCHEMBL28911006 | 0.70 | AGER (0.47) | OPRM1AGERMTNR1ACHRM2CHRM3 | |
| SCHEMBL28544798 | 0.70 | AGER (0.47) | OPRM1AGERMTNR1ACHRM2CHRM3 | |
| SCHEMBL3370759 | 0.70 | AGER (0.55) | OPRM1AGERMTNR1ACHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572813-B2 | Cyclic amide derivative as monocyte chemotactic protein modulator; prevention and treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma; antiinflammatory agents; N-[2-[[(cis) -2-[[1- (4-Chlorophenyl)ethyl]amino]cyclohexyl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-20060135502-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CHERNEY ROBERT | 2006-06-22 | — | — | US | disclosed |
| US-7045521-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040110736-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CHERNEY ROBERT (US) | 2004-06-10 | — | — | US | disclosed |
| US-6706712-B2 | RHEUMATIC DISEASES, MULTIPLE SCLEROSIS, ASTHMA, ANTICHOLESTEROL AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-16 | — | — | US | disclosed |
| US-20030004151-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110736-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | OPRM1 1041/4885AGER 505/4885MTNR1A 352/4885 |
| US-20030004151-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | OPRM1 1041/4885AGER 505/4885MTNR1A 352/4885 |
| US-20060135502-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | OPRM1 1017/4885AGER 424/4885MTNR1A 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.